ObjectivesLow vitamin D and high response of T helper‐17 (Th17) are two main risk factors in multiple sclerosis (MS). The purpose of the present study was to investigate whether vitamin D supplementation can reduce Th17 responses and interleukin‐17A (IL‐17A) production.MethodsSerum samples of 17 relapsing–remitting MS patients were collected at onset of disease. They were supplemented with 50 000 IU/week vitamin D3 for 6 months. After 6 months, sampling was repeated from the patients. The serum level of 25‐hydroxyvitamin D and IL‐17A were measured at baseline, and after 6 months using commercially available enzyme‐linked immunosorbent assay. Statistical analyses were carried out by Wilcoxon test and Spearman's rho correlation coefficient.ResultsThe levels of 25‐hydroxyvitamin D were generally deficient (29.4%) and insufficient (47%) in the patients at baseline. The initial IL‐17A levels (mean 3.9, standard error 0.28) were significantly decreased after vitamin D supplementation (mean 2.2, standard error 0.18, P < 0.0001). Furthermore, a positive correlation was seen between pre‐supplementation IL‐17A levels and reduction after supplementation (Spearman's rho = 0.61, P = 0.008).ConclusionIn the present study, it was shown that vitamin D supplementation could reduce the level of IL‐17A in MS patients, and there was an association between these two risk factors in MS disease.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.